CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Known for producing companies like Karuna Therapeutics, which was sold to Bristol Myers Squibb for $14 billion, and newly ...

A multinational study shed light on which sites to scan for early signs of the disease, but scoring system was less sensitive ...

Ford Is Taking on Expensive EVs and the Toyota RAV4 with Its New 'Model T'—a $30K Mid-Size EV Truck ‘What gives you the right ...

Bristol-Myers Squibb recently reported a strong earnings quarter. **The company raised its full-year revenue guidance by $700 million**. This update reflects robust sales growth from key therapies and ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

A new market analysis projects the Heart Block Therapeutics Market will grow from an estimated USD 3.5 billion in 2025 to a ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Before the Kansas City Chiefs became perennial Super Bowl contenders, Andy Reid led a textbook organizational turnaround.

New York hospitals that get discounted drugs through a controversial federal program are gearing up for a new pilot that they ...